Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were jumping 10.9% higher as of 11:49 a.m. ET on Monday. The nice gain came after Goldman Sachs initiated coverage on Iovance stock with a buy recommendation.
Investors no doubt liked Goldman Sachs’ 12-month price target of $12 for Iovance. Analyst Andrea Tan thinks the biotech stock has an upside potential of more than 100%.
Goldman Sachs isn’t the only Wall Street firm that thinks highly of Iovance. All seven of the analysts covering Iovance who were surveyed by LSEG in November rate the stock as either a buy or strong buy.
There’s a simple reason why Wall Street likes Iovance so much these days. The U.S. Food and Drug Administration (FDA) has set a PDUFA date of Feb. 24, 2024, for its approval decision of lifileucel in treating advanced melanoma. Iovance is ramping up for an immediate U.S. launch, pending FDA approval. The company also expects to submit several other regulatory submission in the first half of 2024 with hopes to expand into Europe and other markets.
Investors shouldn’t buy any stock just because a Wall Street analyst likes it. Risk-averse investors, in particular, will probably be better off considering less volatile stocks.
However, Iovance Biotherapeutics could easily be worth a lot more than its current market cap of $1.4 billion if lifileucel wins regulatory approvals and enjoys a successful launch. My view is that this promising biotech stock is a good candidate to buy for aggressive investors.
10 stocks we like better than Iovance Biotherapeutics
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Iovance Biotherapeutics wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of November 20, 2023
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group and Iovance Biotherapeutics. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
